{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-084844","form_type":"8-K","ticker":"ALDX","cik":"0001341235","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2024-10-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.218451+00:00","generated_at":"2026-05-30T21:20:12.640114+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aldeyra resubmits reproxalap NDA for dry eye disease after positive Phase 3 trial","bullets":["Resubmission includes positive results from FDA-requested symptom trial.","Phase 3 dry eye chamber trial met primary endpoint (ocular discomfort, P=0.004).","If approved, reproxalap would be first chronic dry eye therapy with acute symptom and redness data.","FDA review expected within 6 months of acceptance; acknowledgment in 30 days.","Reproxalap showed acute activity in reducing dry eye symptoms and ocular redness in trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-084844","json":"https://secwatch.observer/filing/0001213900-24-084844.json","markdown":"https://secwatch.observer/filing/0001213900-24-084844.md","text":"https://secwatch.observer/filing/0001213900-24-084844.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1341235/000121390024084844/0001213900-24-084844-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1341235/000121390024084844/ea021662501-8k_aldeyra.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T21:20:12.640114+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}